VKTX - Company ID 0001607678
Viking Therapeutics, Inc. (VKTX) reported net income of -$359.64M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$359.64M | -227.1% |
| FY 2024 | -$109.96M | -28.0% |
| FY 2023 | -$85.89M | -24.7% |
| FY 2022 | -$68.87M | -25.2% |
| FY 2021 | -$54.99M | -39.2% |
| FY 2020 | -$39.49M | -53.2% |
| FY 2019 | -$25.78M | -16.8% |
| FY 2018 | -$22.06M | -7.2% |
| FY 2017 |
Viking Therapeutics, Inc. (VKTX) reported net income of -$359.64M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2014 and fiscal 2025, Viking Therapeutics, Inc.'s net income declined from -$21.88M to -$359.64M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$20.58M |
| -39.7% |
| FY 2016 | -$14.73M | +37.1% |
| FY 2015 | -$23.40M | -6.9% |
| FY 2014 | -$21.88M | - |